Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca is pioneering new ways ...

It sounds too simple to be true. Exercise works just as effectively as a drug to slash the risk of dying from bowel cancer, ...

The trial enrolled patients with NSCLC that had PD-L1 expression on 25% or more cells whose tumours had been completely removed with surgery. Imfinzi is already approved for unresectable ...

the first immunotherapy competitor to AstraZeneca’s Imfinzi for these patients. The approval was based on the KEYNOTE-966 study, which found a statistically significant and clinically meaningful ...

A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

The SMC has also has accepted Cladribine, also known as Mavenclad, for the treatment of relapsing-remitting multiple ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The findings provide insight into which patients may have favorable or inferior responses to immunotherapy for small cell ...

Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key ...